We have been representing patients and their family in drug injury lawsuits for the past 17 years and this is our main practice area.
Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.
Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.
Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.
We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.
If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.
We encourage you to submit a Drug Injury Case Review — it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.
While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.
It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Legal & Medical News: Featured Article
As regards the liver cancer risks that have been mentioned in connection with the hepatitis C drugs Sovaldi and Harvoni, during the past nine months there have been mixed messages about whether there is an apparent side-effect situation or not.
We start our update on this still emerging drug safety issue with this April 2016 Medscape news report, “Liver Cancer Found in Hepatitis C Patients on New Antivirals”, from which we get this excerpt:
In a surprising number of patients with hepatitis C and cirrhosis, hepatocellular carcinoma develops within weeks of starting treatment with direct-acting antivirals, new research suggests.
“I do not think that direct-acting antivirals are directly responsible,” said lead investigator Stefano Brillanti, MD, from the University of Bologna, Italy.
“The hypothesis is that immune surveillance may be reduced too rapidly,” he told Medscape Medical News. “You have an immediate drop in viremia, but also attenuation of inflammation. I think inflammation is a bad thing in terms of hepatitis progression, but it may be a good thing in terms of controlling cancer.”
Then we move forward to this November 2016 article published by PracticeUpdate as part of their Gastroenterology section, “Direct-Acting Antiviral Medications for Hepatitis C Virus Infection Do Not Raise Cancer Risk”, from which we get this more recent information:
Patients with hepatitis C who take direct-acting antiviral medications have been found to be at no higher risk of developing liver cancer than those who do not take the medication. If they do develop liver cancer, however, they might be at an increased risk of more aggressive, infiltrative patterns of cancer.
This finding of a retrospective database study was reported at The Liver Meeting 2016, from November 11 – 15.
Alfredo Alberti, MD, of the University of Padova, Italy, explained, “Data on clinical outcomes in cirrhotic patients with hepatitis C treated with direct-acting antiviral agents are still scanty and controversial. This is the case concerning the development of a liver cancer, one of the most frequent and deadly complications of hepatitis C virus infection.”
We will continue to monitor the medical literature and watch for any drug regulatory agency action concerning the possible association between direct-acting antiviral hepatitis C drugs like Sovaldi and Harvoni with liver cancer diagnoses, be it the initial incidence or a recurrence of the hepatocellular carcinoma.
- Invokana Has New Warning About Risk Of Lower Limb Amputation In Canada
- December 2016: FDA Requires Safety Warnings Label Change For Jardiance
- Long-Term Use Of Prevacid, Prilosec, and Nexium May Lead To Strokes
- Defendants BMS And Pfizer Ask For Eliquis Federal Court Consolidation
- Is Eliquis A Safe Alternative To Warfarin For Patients On Dialysis?
- To Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet
- Viagra – Melanoma MDL Might Include Cialis Lawsuits And Levitra Cases